R. Lee Mosley
R. Lee Mosley received his B.S. (1976) and M.S. (1981) degrees in microbiology from the University of Oklahoma. His M.S. research with Dr. Juneann Murphy focused on glycopeptidic antigenic moieties responsible for T-cell-mediated immune responses to Cryptococcus neoformans. Under the mentorship of Dr. John Klein, Mosley received his Ph.D. degree (1992) from the Department of Biology at the University of Tulsa for his work on the immunobiology of intestinal intraepithelial lymphocytes (IELs). As a Postdoctoral Fellow at the Department of Pathology at the University of Michigan Medical Center and the Department of Pathology and Experimental Toxicology at Parke-Davis Pharmaceutical Research Division, he assessed the involvement of intestinal T lymphocytes in murine models of inflammatory bowel disease (IBD). In 1994, Mosley joined Dr. Richard Miller’s Laboratory at the Department of Pathology at the University of Michigan Medical School as an Assistant Research Professor, where he addressed mechanisms of diminished T-cell immunity in the context of a constricting TCR repertoire in both CD4+ and CD8+ T lymphocyte subsets. Mosley joined the University of Nebraska Medical Center as an Assistant Professor, where he expanded his research efforts to include the effects of calorie restriction on the aged T-cell repertoire, the loss of costimulatory molecules on T-cell activation, and the use of bone-marrow-derived growth factors, such as GM-CSF and Flt3 ligand to augment peripheral and mucosal T-cell-mediated immunity. In 2002, Mosley joined the Center for Neurovirology and Neurodegenerative Disorders (CNND) as Chief of the Immunology and Movement Disorders Program to focus on vaccine and immunoregulatory therapies for neurodegenerative disorders such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Biography Updated on 21 November 2012